Biomedical Engineering Reference
In-Depth Information
29. Cortes, J., Baccarani, M., Guilhot, F., Druker, B., Branford, S., Kim,
D., Pane, F., Rudoltz, M., Yu, R., Collins, L., Krahnke, T., Radich, J., and
Hughes, T. (2008) A phase III, randomized, open-label study of 400 Mg
versus 800 Mg of imatinib mesylate (IM) in patients (pts) with newly
diagnosed, previously untreated chronic myeloidLeukemia in chronic
phase (CML-CP) using molecular endpoints: 1-year results of TOPS
(tyrosine kinase inhibitor optimization and selectivity) study,
Blood
, Abstract 335.
30. Petzer, A., Wolf, D., Fong, D., Lion, T., Dyagil, I., Masliak, Z., Boskovic,
D., Griskevicius, L., Lejniece, S., Goranov, S., Gercheva, L., Stojanovic,
A., Peytchev, D., Tzvetkov, N., Griniute, R., Oucheva, R., Ulmer, H.,
Kwakkelstein, M., Fincato, G., and Gastl, G. (2008) CELSG CML 11
“ISTAHIT” phase III study—planned interim analysis: high doses of
imatinib mesylate (800 mg/day) significantly improve rates of major
and complete cytogenetic remissions (MCR, CCR) in pretreated Ph+/
BCR-ABL+ CML patients in chronic phase.,
(ASH Annual Meeting Abstracts) 112
, 112, Abstract 1112.
31. Hughes, T., and Branford, S. (2003) Molecular monitoring of chronic
myeloid leukemia,
Blood
40, pp. 62-68.
32. Kaeda, J., Chase, A., and Goldman, J. M. (2002) Cytogenetic and molecular
monitoring of residual disease in chronic myeloid leukaemia,
Semin. Hematol.,
Acta.
, 107, pp. 64-75.
33. Schiffer, C. A. (2007) BCR-ABL tyrosine kinase inhibitors for chronic
myelogenous leukemia,
Haematol.
, 357, pp. 258-265.
34. Thomas, J., Wang, L., Clark, R. E., and Pirmohamed, M. (2004) Active
transport of imatinib into and out of cells: implications for drug
resistance,
N. Engl. J. Med.
, 104, pp. 3739-3745.
35. O'Hare, T., Eide, C. A., and Deininger, M. W. (2007) BCR-ABL kinase
domain mutations, drug resistance, and the road to a cure for chronic
myeloid leukemia,
Blood
, 110, pp. 2242-2249.
36. Branford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., Taylor,
K., Herrmann, R., Seymour, J. F., Arthur, C., Joske, D., Lynch, K., and
Hughes, T. (2003) Detection of BCR-ABL mutations in patients with
CML treated with imatinib is virtually always accompanied by clinical
resistance, and mutations in the ATP phosphate-binding loop (P-loop)
are associated with a poor prognosis,
Blood
, 102, pp. 276-283.
37. Jabbour, E., Kantarjian, H., Jones, D., Talpaz, M., Bekele, N., O'Brien, S.,
Zhou, X., Luthra, R., Garcia-Manero, G., Giles, F., Rios, M. B., Verstovsek,
S., and Cortes, J. (2006) Frequency and clinical significance of BCR-
ABL mutations in patients with chronic myeloid leukemia treated with
imatinib mesylate,
Blood
Leukemia,
20, pp. 1767-1773.
